Product Description
ORM-6151/BMS-986497 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader initially developed by Orum Therapeutics for the treatment of acute myeloid leukemia (AML) and other CD33-expressing malignancies. (Sourced from: https://www.orumrx.com/pipeline-page)
Mechanisms of Action: GSPT1 Degrader,CD33 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BMS-986497](https://pryzm-maps.s3.us-west-2.amazonaws.com/483current_maps.png)
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CA235-0001 | P1 |
Recruiting |
Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome |
2027-02-01 |